KPRX – kiora pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study [Yahoo! Finance]
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences [Yahoo! Finance]
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting [Yahoo! Finance]
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases [Yahoo! Finance]
Form 8-K KIORA PHARMACEUTICALS For: May 01
Form EFFECT KIORA PHARMACEUTICALS
Form 424B3 KIORA PHARMACEUTICALS
Form DEF 14A KIORA PHARMACEUTICALS For: May 01
Form 8-K KIORA PHARMACEUTICALS For: Mar 25
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.